Europe
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The company is expanding its manufacturing efforts in Europe, Canada, the United Kingdom and the United States in order to meet this goal.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Questions over the efficacy and safety of hydroxychloroquine continue to be raised following the World Health Organization’s decision to temporarily halt a study of the malaria drug as a potential treatment for COVID-19.
Argenx, based in Breda, the Netherlands, and Ghent, Belgium, announced positive topline results from its Phase III ADAPT clinical trial of efgartigimod for Myasthenia Gravis (MG).
Sanofi is selling off its nearly $13 billion in investments in longtime development partner Regeneron as the France-based company shifts its strategy to focus on indications such as oncology, neurology, rare diseases and hematology.
Heading into the first week after Memorial Day, which in the U.S. marks the typical beginning of summer, the U.S. Food and Drug Administration has a number of drug approvals on the calendar. Here’s a look.
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
PRESS RELEASES